Atopic Dermatitis Drug Market – Global Industry Insights, 2025

Atopic dermatitis, also known as eczema, is a condition in which skin becomes dry, itchy, and inflamed, which leads to redness, swelling, scaling, and crusting. Atopic dermatitis is commonly found in children under one year. The exact cause of atopic dermatitis is undiscovered, but it is believed that it includes genetics, environmental exposure, immune system dysfunction, and problem with skin permeability. Dry climate is also a major cause of atopic dermatitis. This disease is non-contagious and easily diagnosed with signs and symptoms such as swelling and redness of skin. Many people with atopic dermatitis develop asthma and hay fever. Atopic dermatitis treatment involves photo therapy, steroid pills, calcineurin inhibitors ointment, biologic agents such as immunologic, monoclonal antibody, and dietary changes in case of food allergy.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/712

Atopic Dermatitis Drug Market Taxonomy

By End User;

Hospitals
Clinics
Research Labs
By Route of Administration;

Injectable
Oral
Topical
By Therapy;

Photo Therapy
Directed Therapy

Topical steroids and development of new drugs fuel the atopic dermatitis drug market

Atopic dermatitis treatment majorly relies on topical steroids and hence the segment holds the largest market share. A lukewarm bath followed by the application of moisturizer helps in the treatment of atopic dermatitis. Immunomodulators and pimecrolimus are also used for the treatment of atopic dermatitis. According to the American Academy of Dermatology, in 2016, there were around 28 million people of all age groups affected by atopic dermatitis in the U.S. The expected launch of dupilumab, monoclonal antibody developed by Sanofi and Regeneron Pharmaceuticals Inc. in 2017, which is approved by FDA for the treatment of atopic dermatitis plays a major role in the treatment of the disease and supports the growth of atopic dermatitis drug market. In December 2016, the crisaborole ointment was approved by FDA for the treatment of mild atopic dermatitis. When such drugs are launched, FDA issues black box warning on the label of prescribed drug to warn users about the side effects. It is expected that new product launches in near future will significantly boost the atopic dermatitis drug market. This market offers opportunities to the companies involved in the development of novel drugs and therapies as there is an extensive need for developed medications with high safety and efficiency. Major challenges faced by atopic dermatitis drug market are side effects, high cost of treatment, and lack of good & safe therapeutics, which hinder the market growth.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/atopic-dermatitis-drug-market-712

Developed regions support the growth of atopic dermatitis drug market

On the basis of geography, the global atopic dermatitis drug market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the atopic dermatitis drug market due to increasing number of atopic dermatitis cases and high R&D investment for the development of atopic dermatitis drug. The increase in food and skin allergies raised the atopic dermatitis cases in infants, which in turn fuels the atopic dermatitis drug market growth. Europe is the second largest market for atopic dermatitis drugs followed by Asia Pacific. Asia Pacific is a flourishing market owing to the prevalence of atopic dermatitis and increased demand for drugs in emerging countries such as India and China. The market is expected to expand at a high rate in the near future, supporting the global atopic dermatitis drug market.

Key Players in the Global Atopic Dermatitis Drug Market

Major players in the market use different strategies such as mergers and acquisitions in order to acquire high market share and attain a competitive edge. In 2016, Novartis AG acquired Ziarco, which adds oral atopic dermatitis drug to its product pipeline. Pfizer acquired Anacor Pharmaceuticals in 2016 allowing access to non-steroidal topical gel, crisaborole, approved by FDA for atopic dermatitis treatment. Some of the key players in the market are Bayer Healthcare, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, and Novartis AG.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.